Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

Investors Have Been Waiting to Buy the Dip in This Hot Biopharma Stock

  • Jazz Pharmaceuticals (JAZZ) is a specialty biopharma company focused on neuroscience and oncology.
  • JAZZ exhibits strong technical momentum. Shares are up nearly 50% over the past year.
  • The stock maintains a 100% “Buy” technical opinion from Barchart.
  • Wall Street sentiment is bullish with multiple “Strong Buy” ratings and price targets up to $275.

Today’s Featured Stock

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.